112626-91-2

Usage

Uses

Used in Pharmaceutical Synthesis:
(4-BROMO-3-METHYL-PHENYL)-HYDRAZINE is used as a reagent in the pharmaceutical industry for the synthesis of various organic compounds. Its unique structure allows it to be a key intermediate in the production of drugs, contributing to the development of new medications.
Used in Dye and Pigment Production:
In the dye and pigment industry, (4-BROMO-3-METHYL-PHENYL)-HYDRAZINE is utilized as a precursor in the development of dyes and pigments. Its chemical properties enable the creation of a wide range of colorants used in various applications, such as textiles, plastics, and printing inks.
Used in Organic Chemistry Research:
(4-BROMO-3-METHYL-PHENYL)-HYDRAZINE is employed as a research compound in organic chemistry, where it is used to explore new reactions and mechanisms. Its presence in experiments aids in understanding the behavior of hydrazine derivatives and their potential in creating novel organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (4-BROMO-3-METHYL-PHENYL)-HYDRAZINE is used as a building block for the design and synthesis of new pharmaceutical agents. Its structural features make it a valuable component in the development of drugs with specific therapeutic targets.
Used in Materials Science:
(4-BROMO-3-METHYL-PHENYL)-HYDRAZINE is also utilized in materials science for the development of new materials with unique properties. Its integration into various compounds can lead to advancements in areas such as polymer science, nanotechnology, and material coatings.

Upstream product

• 615-59-8 1,4-dibromo-2-methylbenzene 
• 6933-10-4 amino-5-bromo-2-toluene 

Downstream Products

• 858523-45-2 1-(4-bromo-3-methylphenyl)pyrazole 
• 109454-31-1 D-(1R)-1-[2-(4-bromo-3-methyl-phenyl)-2H-[1,2,3]triazol-4-yl]-erythritol 

Relevant academic research and scientific papers

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

Synthesis of Aryl Hydrazines via CuI/BMPO Catalyzed Cross-Coupling of Aryl Halides with Hydrazine Hydrate in Water

The N,N’-bis(2,6-dimethylphenyl)oxalamide was discovered as a powerful ligand for Cu-catalyzed cross-coupling of aryl halides with hydrazine hydrate, leading to the formation of a variety of aryl hydrazines at 80 oC in water under the assistance of K3PO4 and 4 mol% cetyltrimethylammonium bromide from aryl bromides and aryl iodides. Good to excellent yields were observed in most cases.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure (a) including pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist and a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.